Home World News Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced... World News Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression By Ogkologos - July 16, 2025 800 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATRACTIB study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Synchronized Swimmer Learns She Has Breast Cancer After Teammate Kicks Her... March 4, 2020 Kelly Preston, Actress And Wife Of John Travolta, Dies From Breast... July 13, 2020 Delayed irAEs Occur in a Small Subset of Patients with Melanoma,... April 1, 2021 Sotorasib Shows Promising Activity and Acceptable Safety in Patients with Previously... January 10, 2023 Load more HOT NEWS Can Cooking With Nonstick Cookware Increase Your Cancer Risk? Carriers of a Germline Pathogenic Variant in CDKN2A are at a... The Late Alex Trebek’s Wardrobe Is Being Given to Homeless Men... EMA Publishes Guidance to Provide Key Methods and Good Regulatory Practices...
